581-50-0

应用筛选条件

关键词:'581-50-0'

显示 1-1 共 1 条结果关于 "581-50-0" 范围论文

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Gunter von Minckwitz et al.

The Lancet. Oncology, 15(7), 747-756 (2014-05-06)

Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy

1/1